Eli Lilly Profit Sinks on Patent Expirations

Eli Lilly said its second-quarter profit slid 39% as patent expirations for some of its bigger-selling drugs dragged down revenue and volume.



from WSJ.com: US Business http://ift.tt/1kXsuTc

via IFTTT